Insider sale details
Nathan L. Mata, the Chief Scientific Officer of BELITE BIO, INC (NASDAQ: BLTE), executed the sale of 1,000 American depositary shares on April 20, 2026. The total proceeds from the transaction were $163,594. Trade prices for the shares in the sale ranged from $162.7552 to $168.35, and at the time of reporting the company's shares were trading at $165.23.
The transactions were completed under a Rule 10b5-1 trading plan that Mr. Mata adopted on December 10, 2025. After these disposals Mr. Mata retained direct ownership of 12,666 American depositary shares in the company. Each American depositary share represents one ordinary share of the issuer.
Analyst views and market context
Analysts covering Belite Bio continue to show optimism about the company's outlook. Reported price targets for the stock range from $185 to $266. The company has attracted attention from research subscribers, with InvestingPro noted as offering additional ProTips and Pro Research Reports on BLTE and more than 1,400 other U.S. equities.
Regulatory progress and clinical program
Belite Bio has begun a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for tinlarebant, an oral therapy being developed for Stargardt disease type 1. The company is aiming to finish the submission by the second quarter of 2026. The FDA has granted Breakthrough Therapy Designation for the treatment.
Analysts have responded to the regulatory progress and clinical results. H.C. Wainwright reiterated a buy rating and raised its price target to $200, citing positive results from the Phase 3 DRAGON trial. Benchmark also maintained a buy rating, pointing to Belite Bio's reported cash position of $353 million and $420 million in investments, which Benchmark estimates provides more than two years of financial runway. Benchmark expects the company to allocate substantial resources to research and development and to sales and marketing efforts in support of a commercial launch for tinlarebant. Mizuho likewise reiterated an Outperform rating and noted a refined NDA submission timeline with potential approval in early 2027.
Summary of the current position
The insider sale by the company's CSO occurred concurrently with sustained share appreciation over the past year and as the company moves through an active regulatory filing process for tinlarebant. Analysts retain constructive ratings and a range of price targets, while research firms and sell-side analysts emphasize the company's reported cash and investment balances and the need to fund development and commercialization activities.